Enteric Disease Testing Market Size & Share 2025 - 2034

Enteric Disease Testing Market Size

The global enteric disease testing market size was valued at USD 2.2 billion in 2024. The market is expected to reach from USD 2.3 billion in 2025 to USD 3.3 billion in 2034, growing at a CAGR of 4.2% during the forecast period. The high market growth is attributed to the increasing incidence of enteric infections globally, rising awareness and surveillance initiatives, technological advancements in diagnostic testing, and surging demand for point-of-care testing (POCT), among other contributing factors.

The growing incidence of enteric diseases such as cholera, salmonellosis, rotavirus, and amoebiasis is increasing market growth. As per the World Health Organization (WHO) 29 countries reported cholera cases in 2022 with a staggering figure of 472,697 cases and 2,348 deaths globally. These infections are mainly seen in low- and middle-income countries because of the lack of proper sanitation facilities and contaminated water supplies. There is ongoing need for timely and reliable diagnostics as these infections are characterized by recurrent outbreaks along with endemic persistence. Early detection through appropriate testing facilitates effective interventions, leading to improved patient outcomes and better control efforts beyond mere avoidance.
 

Moreover, the rising popularity of capsule endoscopy, ingestible sensors, as well as drug delivery systems have emphasized the need for functional testing of enteric devices pertaining to dissolution, transit time considerations, as well as localized release within gastrointestinal structures. As developers pursue accuracy validation for inventive mechanisms, the emphasis on precision reinforces market growth vis-a-vis this trend.
 

Enteric disease testing refers to the diagnostic processes used to detect infections that affect the gastrointestinal tract, typically caused by bacteria, viruses, or parasites. These tests focus on identifying infectious agents for conditions such as diarrhea, typhoid, cholera and dysentery. Common testing methods include stool culture, antigen detection, molecular assays and multiplex PCR panels. The aim is to facilitate prompt diagnosis and treatment, during outbreaks and in high burden areas.
 

Enteric Disease Testing Market Trends

The market is witnessing significant growth, driven by the shift toward molecular and multiplex testing technologies, the rise of point-of-care and rapid diagnostic tests (RDTs), increasing adoption of syndromic testing panels, surging need for AI and automation in diagnostics, and growing emphasis on One health and global surveillance, among other factors.
 

• Hospitals and other healthcare facilities are implementing molecular diagnostic procedures such as PCR and multiplex assays for the detection of enteric diseases. As noted by the Centers of Disease Control and Prevention (CDC) in 2023, molecular diagnostic testing for enteric pathogens has increased diagnostically in clinical labs by 45% within the U.S. The tests have a singular approach whereby they determine multiple pathogens; hence bacteria, viruses, and even parasites can be tested at once using a single sample with precision. The results provided using molecular methods are accurate and rapid, and they are increasingly replacing routine culture and microscopic techniques used in clinical settings.
   
• Further, the use of syndromic panels is becoming common practice in hospitals and laboratories for patients presenting gastrointestinal symptoms. These panels are designed to test for broad ranges within numerous pathogens based on symptom complexes rather than singular organisms which makes this trend favorable. This trend enhances overall efficiency during diagnosis while also enabling precise therapy thus reducing empirical treatment which is important to curb antimicrobial resistance.
   
• In addition, there is growing interest in test kits that are easy to use, portable and provide instant results especially at the outbreak zones and resource limited regions. Point-of-care has almost instant test result delivery systems that do not require sophisticated laboratory facilities. Such clinics are indispensable in remote areas among patients requiring urgent attention as well as emergency services, making them crucial in field epidemiology which increases their demand among NGOs and global health organizations ultimately increasing the market further.
   

Enteric Disease Testing Market Analysis

Based on disease, the market is segmented into bacterial enteric disease, viral enteric disease, and parasitic enteric disease. The bacterial enteric disease segment has asserted its dominance in the market by securing a significant market share of 55.1% in 2024 and is anticipated to grow at a CAGR of 4.6% over the forecast years.
 

• The bacterial enteric disease segment holds the dominant market share in the global market. This dominance is primarily due to the high worldwide incidence of bacterial infections, as foodborne diseases are among the leading causes of sickness and death around the world; salmonella, shigella, e. coli, and campylobacter are responsible for over 550 million illnesses and 230 thousand deaths annually according to WHO. Furthermore, in 2025 CDC reported that more than 9 million people in the U.S. suffered from foodborne illness. This not only creates a significant public health burden but also necessitates extensive diagnostic testing.
   
• The severe symptoms and rapid onset associated with bacterial zoonoses coupled with their potential to cause widespread outbreaks make them the most commonly screened pathogens in stool examination especially in sensitive institutions like hospitals, daycare centers, nursing homes and food production plants.
   
• In addition, the increasing rates of antimicrobial resistance (AMR) globally makes routine identification of bacterial pathogens and profiling their antibiotic susceptibility increasingly critical. There is rising concern regarding drug resistant strains of Shigella and Campylobacter in North America and Asia which requires comprehensive testing methods causing them to be flagged in the 2024 AMR Surveillance Report framing stricter guidelines leading to advanced testing setups.
   

Based on test type, the enteric disease testing market is classified into immunoassay, molecular, conventional, chromatography & spectrometry, and other test types. The immunoassay segment accounted for the highest market revenue of USD 790.6 million in 2024 and is poised to grow at a CAGR of 4.3%.
 

• The leading position in the market is maintained due to higher clinical utilization of ELISA, LFA, and CLIA testing for enteric pathogens detection. This is especially true in low resource settings and for point-of-care tests. As highlighted in a 2023 report from CDC and GFN WHO, immunoassays are still the predominant method employed for routine surveillance and outbreak response program for bacterial toxins, rotavirus, and norovirus detection.
   
• Furthermore, recent collaborations between organizations such as the Foundation for Innovative New Diagnostics (FIND) and diagnostic manufacturers have resulted in expanded access to CLIA-based multiplex immunoassays, particularly in Asia, Africa, and Latin America. These efforts have improved the availability of quantitative and semi-quantitative immunoassay platforms in public health laboratories for enteric disease surveillance.
   
• Although molecular testing is gaining momentum, immunoassays continue to be the frontline diagnostic method for their affordability, minimal equipment requirements, and regulatory support. All these factors make contributing to its market dominance.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the enteric disease testing market is categorized into hospitals, diagnostic laboratories, research & academic institutes, and other end users. The hospitals segment dominated the market in 2024 and accounted for USD 998.3 million and is anticipated to grow at a CAGR of 4.4% during the forecast period.
 

• Hospitals are the largest end user segment in the market due to their role in acute care and emergency department presentations. As a primary responder, hospitals receive most patients suffering from severe gastrointestinal manifestations, especially those wishing for immediate clinical assistance due to foodborne illnesses.
   
• Hospital-based laboratories process most of the urgent cases for enteric diseases due to frequent visits by patients presenting with gastrointestinal complaints. This segment is motivated by the increasing need of rapid results driven by critical time-sensitive clinical interventions, particularly in emergency departments. To satisfy this challenge, hospitals are keen on providing high-demand point-of-care evaluations and fast-responding molecular diagnostics offering comprehensive pathogen panels within hours.
   
• In addition, integrated electronic health records (EHR) systems together with laboratory information systems (LIS) improve workflow optimization and provide real-time clinical workflow strategies during patient care. In addition, continuous-access automated molecular diagnostic systems that minimize hands-on operational time while optimizing test retrieval are actively being adopted by hospitals.
   

U.S. enteric disease testing market was valued at USD 755 million and USD 776 million in 2021 and 2022, respectively. The market size reached USD 822.4 million in 2024, growing from USD 798.6 million in 2023.
 

• The U.S. reports millions of cases of foodborne illnesses every year, with pathogens like Salmonella, E. coli, and Norovirus leading the charge. The CDC estimated in 2022, that Salmonella infections accounted for 1.35 million cases, 26,500 hospitalizations, and 420 deaths in the U.S. Responding to this ongoing challenge to public health will necessitate regular precision enterics testing. The Centers for Disease Control and Prevention (CDC) surveillance programs and alert systems motivate a wide-ranging hospital and laboratory commensurate with comprehensive diagnostic protocols.
   
• Furthermore, the governmental bodies like the CDC or even FDA and USDA respond to outbreaks of enteric diseases as well. Programs like FoodNet or PulseNet are vital for improving early outbreak detection as they use sophisticated laboratory-based tests to ensure accuracy. Working under these conditions drives continuous innovation regarding diagnostics which must be able to identify pathogens quickly.
   
• In addition, the commercial labs along with hospital networks and academic research centers provide aid for the diagnostic lab ecosystem in America which is very advanced. Increased investments into automated analyzers or AI-driven platforms will help improve access towards centralized networks which aim at enteric disease testing. These enhanced capabilities help meet clinical demand across various regions while increasing test accuracy, thereby improving the country's economy.
   

Europe enteric disease testing market accounted for USD 606 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The market for testing enteric diseases in Europe is growing due to increasing concern for public health, the sustained burden of gastrointestinal infections, as well as international traveling. Europe also has a well-developed healthcare system and surveillance infrastructure which enables access to diagnostic testing and timely response to outbreaks.
   
• Enteric infections such as campylobacteriosis, salmonellosis, norovirus infection, and giardiasis are some of the most prevalent infections across the region caused by bacteria, viruses, and other parasites.
   
• As per the European Food Safety Authority (EFSA) campylobacteriosis remains prevalent within foodborne illnesses with over 246,000 confirmed cases yearly making it lead in Europe. Salmonellosis is a close follower with approximately 88,000 cases reported each year.
   
• Moreover, norovirus is a leading cause of viral gastroenteritis and is responsible for 145 confirmed foodborne outbreaks linked to fish and fishery products. Giardiasis, while less prevalent, still accounted for 18,004 confirmed cases in the EU in a recent reporting year.
   

UK enteric disease testing market in the Europe is projected to grow remarkably in the coming years.
 

• The UK's global trade links and dependence on foreign food imports elevates the risk of contracting travel-associated enteric infections and pathogens that spread through international borders. Travel health clinics, customs screening, and NHS diagnostic facilities undertake testing for returnees with diarrhea symptoms regularly. This increases the need for efficient broad spectrum and rapid diagnostics.
   
• UK laboratories have started utilizing multiplex PCR panels which detect a wide array of bacterial, viral, and parasitic pathogens from a single stool sample. These advanced diagnostic techniques improve clinical decision-making as well as reduce turnaround time. In addition, the shift of NHS towards precision medicine along with centralized diagnostic laboratories reinforces this pattern.
   

The Asia Pacific enteric disease testing market is anticipated to grow at the highest CAGR of 5.2% during the analysis timeframe.
 

• The Asia Pacific market is expanding rapidly owing to the region’s disproportionately high rate of gastrointestinal infections, growing healthcare infrastructure, as well as heightened concern regarding food and water safety.
   
• Countries like India and China continue to face challenges such as poor sanitation, limited access to clean water, and overcrowded urban centers, all of which contribute to persistently high rates of bacterial, viral, and parasitic enteric diseases.
   
• In addition to the growing burden of complicated infections that require extensive medical intervention, these regions continue to struggle with common enteric diseases such as cholera, typhoid fever, shigellosis, hepatitis A, and parasitic infections like giardiasis and amoebiasis.
   
• The public continues to observe that, especially during monsoon seasons or in areas affected by natural disasters, there are rapid outbreaks of various infectious diseases requiring immediate containment. As a result, both governments and public health organizations are increasing investments to improve surveillance systems and diagnostic infrastructure, enabling better early detection and prevention.
   

China holds a dominant position in the Asia Pacific enteric disease testing market.
 

• With the establishment of the Chinese Center for Disease Control and Prevention (China CDC), China has made significantly large investments in the country’s infrastructure. In 2023, the Chinese government allocated around USD 369 billion towards public health structural development. This investment would build a stronger competitive position on infectious disease control and monitoring on a global level.
   
• The country has geared its comprehensive disease surveillance systems to monitor gastrointestinal outbreaks during peak seasonal periods. This surveillance system enhances the overall use of diagnostic tools throughout hospitals, community clinics, and regional medical centers.
   
• Rapid urban growth within the country along with increased complexity within its food supply chains are elevating risks for foodborne diseases. There is rising concern from the public regarding incidences related to mass catering, meat processing, and imported foods. This has resulted in greater food safety monitoring by both government agencies and private organizations through diagnosing screening at all levels of the supply chain.
   

The Brazil enteric disease testing market is experiencing robust growth in Latin America market.
 

• The Brazilian Ministry of Health actively monitors enteric diseases through national programs like SINAN (Sistema de Informação de Agravos de Notificação). These programs enable the reporting of gastro-intestinal infections and help to manage infection control. There is an ongoing national focus on improving healthcare provider awareness which is broadening access to essential services and diagnostic infrastructure.
   
• The Unified Health System (SUS) is progressively enhancing the laboratory infrastructure in addition to expanding the health care delivery system at various levels. The equipping of regional hospitals and clinics with modern diagnostic tools is facilitating the early detection of enteric diseases. These investments are particularly impactful in underserved regions where the burden of disease is high and timely diagnosis is crucial.
   

Saudi Arabia enteric disease testing market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• Under Vision 2030, Saudi Arabia is heavily investing in healthcare infrastructure, including laboratory expansion, diagnostic automation, and disease surveillance. The push toward digital health and preventive care includes improving the country's ability to detect and manage infectious diseases. These strategic reforms are facilitating the adoption of modern diagnostic platforms for enteric illnesses.
   
• Additionally, infants and children under five years of age in the Kingdom bear the greatest burden of enteric infections. To prevent further health deterioration and reduce unnecessary hospitalizations, pediatric hospitals and primary healthcare centers have implemented comprehensive early screening programs. Government-sponsored health initiatives continue to prioritize the control of diarrheal diseases, thereby increasing the demand for relevant diagnostic services.
   

Enteric Disease Testing Market Share

The global market is moderately consolidated, with prominent pharmaceutical and diagnostics companies leading space, while innovation continues to thrive among emerging players and specialized firms. Major market participants such as Abbott Laboratories, bioMérieux, Danaher and Becton, Dickinson and Company holds around 20-25% market share in the global market, These players are actively pursuing strategic initiatives to enhance their market presence and address the growing demand for accurate and rapid enteric disease diagnostics. These industry leaders are leveraging product innovation, strategic partnerships, acquisitions, and geographic expansion to stay competitive and meet evolving clinical needs.
 

Enteric Disease Testing Market Companies

Prominent players operating in the enteric disease testing industry include:

• Abbott Laboratories
• Becton, Dickinson and Company
• Biomerica
• bioMérieux
• Bio-Rad Laboratories
• Coris BioConcept
• Danaher
• DiaSorin
• Merck KGaA
• Meridian Bioscience
• Techlab
• Thermo Fisher Scientific
   
• Abbott stands out with its fully integrated, automated molecular platforms like the Alinity and m2000 systems, offering a comprehensive infectious disease testing menu that includes enteric pathogens. Their rapid, high-throughput architecture streamlines workflows, supports disease surveillance programs, and enhances lab efficiency.
   
• Thermo Fisher excels in rapid multiplex PCR testing, such as the SureTect and RapidFinder systems, enabling simultaneous detection of several enteric pathogens in a single run. These validated, user-friendly workflows significantly reduce time-to-result and simplify lab operations.
   

Enteric Disease Testing Industry News:

• In June 2023, Avacta acquired Coris Bioconcept, retaining it as the sole diagnostics asset after divesting other segments. This move aligns with Avacta's strategy to transition into a pure-play biotech company.
• In January 2023, SD Biosensor and SJL Partners completed the acquisition of Meridian Bioscience on January 31, 2023. Following the transaction, Meridian ceased trading on NASDAQ and continued operations under new ownership.
   
• In June 2021, Bio-Rad partnered with Seegene to co-develop and commercialize multiplex molecular diagnostic tests. These tests are designed for use on Bio-Rad’s CFX96 Dx Real-Time PCR System, which supports syndromic testing a method often used in enteric disease diagnostics. This partnership strengthened Bio-Rad’s molecular diagnostics portfolio.
   

The enteric disease testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease

• Bacterial enteric disease
  • Salmonella
  • E. coli
  • Campylobacter
  • C. difficile
  • Shigellosis
  • Listeria
• Viral enteric disease
  • Rotavirus infection
  • Norovirus infection
• Parasitic enteric disease
  • Giardiasis
  • Amebiasis
  • Cryptosporidiosis

Market, By Test Type

• Immunoassay
• Molecular
• Conventional
• Chromatography & spectrometry
• Other test types

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Research & academic institutes
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE